All In Biotech

Drug Trial Radar · NCT05180461

Emodepside Phase II Trial for Treatment of Onchocerciasis

A Phase-II, Randomised, Double-blind, Parallel-group Trial to Investigate Emodepside (BAY 44-4400) in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Pharmacodynamics, Pharmacokinetics and Dose-Response Relationship for Efficacy (Proof-of-Concept); Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics

Last checked: Nov 20, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 578 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

578

Planned (sponsor's estimate)

Start

Aug 30, 2021

Primary completion

Sep 18, 2026

Study completion Oct 2, 2026

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bayer
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.

Conditions

  • Onchocerciasis

Interventions

  • emodepsideDrug

    emodepside tablet

  • matching placebo of emodepsideDrug

    emodepside matching placebo tablet

  • ivermectinDrug

    ivermectin tablet (overencapsulated for blinding)

  • matching placebo of ivermectinDrug

    matching placebo of overencapsulated ivermectin tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - absence (or presence) of live female adult worms with normal embryogenesisTime frame: 12 months
  2. Part 1 - absence (or presence) of skin microfilariae (co-primary outcome)Time frame: 12 months
  3. Part 2 - absence (or presence) of skin microfilariaeTime frame: 24 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Centre de santé de référence de Kimpese

    Kimpese, Bas-Congo Province, Democratic Republic of the Congo

  • Hôpital général de référence de Masimanimba

    Masi-Manimba, Kwilu, Democratic Republic of the Congo

  • University of Health and Allied Services School of Public Health

    Hohoe, Volta Region, Ghana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.